title: The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism.
abstract: The present in vivo microdialysis study demonstrated that the subcutaneous injection of modafinil (diphenyl-methyl-sulfinyl-2-acetamide) in doses of 30-300 mg/kg dose dependently increased dopamine release from the intermediate level of the nucleus accumbens along the rostro-caudal axis of the halothane anaesthetized rat. The effect of modafinil in a dose of 100 mg/kg was counteracted by the local perfusion in the nucleus accumbens with the GABAB receptor antagonist phaclofen (beta-p-chlorophenyl-gamma-aminopropyl-phosphonic acid) (50 microM), the GABAA agonist muscimol (3-hydroxy-5-aminomethyl-isoxazolol) (10 microM) and the neuronal GABA reuptake inhibitor SKF89976A (4,4-diphenyl-3-butenyl-nipecotic acid) (0.1 microM), whereas it was increased by the GABAB receptor agonist (-)-baclofen [beta-(p-chlorophenyl-gamma-aminobutyric acid)] (10 microM). In addition, the modafinil-induced increase of dopamine release was associated with a significant reduction of accumbens GABA release. These results suggest that the dopamine releasing action of modafinil in the rat nucleus accumbens is secondary to its ability to reduce local GABAergic transmission, which leads to a reduction of GABAA receptor signaling on the dopamine terminals.
authors.affiliation: Institute of Pharmacology, University of Ferrara, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Ferraro
authors.forename: S
authors.initials: S
authors.lastname: Tanganelli
authors.forename: W T
authors.initials: WT
authors.lastname: O'Connor
authors.forename: T
authors.initials: T
authors.lastname: Antonelli
authors.forename: F
authors.initials: F
authors.lastname: Rambert
authors.forename: K
authors.initials: K
authors.lastname: Fuxe
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001418:Baclofen / Q000031:analogs & derivatives / Q000494:pharmacology; D001559:Benzhydryl Compounds / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D008297:Male; D000077408:Modafinil; D009118:Muscimol / Q000494:pharmacology; D009557:Nipecotic Acids / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D005680:gamma-Aminobutyric Acid / Q000032:analysis / Q000378:metabolism*
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D018755:GABA Agonists; D018756:GABA Antagonists; D009557:Nipecotic Acids; C052329:phaclofen; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; C045598:N-(4,4-diphenyl-3-butenyl)nipecotic acid; D001418:Baclofen; D000077408:Modafinil; D004298:Dopamine